ABT-888 (Veliparib): Potent PARP1/2 Inhibitor for DNA Repair Inhibition

Executive Summary: ABT-888, also known as Veliparib, is a selective and potent inhibitor of PARP1 (Ki = 5.2 nM) and PARP2 (Ki = 2.9 nM) enzymes, critical mediators of DNA repair (APExBIO). By impeding PARP-mediated single-strand break repair, ABT-888 sensitizes tumor cells—especially those with defective DNA repair genes—to chemotherapy and radiation (Pettenger-Willey et al., 2026). Its high purity (>99.5%) and solubility profile make it suitable for reproducible in vitro and in vivo research. The compound shows efficacy in microsatellite instability (MSI) tumor models, including colorectal cancer xenografts. ABT-888 is for research use only and is not approved for clinical therapy.

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are enzymes that detect and signal single-strand DNA breaks (SSBs). PARP1 and PARP2 catalyze ADP-ribosylation of target proteins, facilitating recruitment of DNA repair factors. Inhibition of PARP activity leads to persistence of SSBs, which can convert to double-strand breaks during replication (Pettenger-Willey et al., 2026). Cells with deficiencies in homologous recombination repair (e.g., BRCA1, BRCA2, MRE11, RAD50 mutations) are especially sensitive to this mechanism, a concept known as synthetic lethality. In MSI tumor models, defective DNA repair pathways further enhance sensitivity to PARP inhibition (Strategic PARP Inhibition with ABT-888).

Mechanism of Action of ABT-888 (Veliparib)

ABT-888 (Veliparib) inhibits the catalytic activity of PARP1 and PARP2 by binding to their NAD⁺-binding domains. The inhibition constants (Ki) are 5.2 nM for PARP1 and 2.9 nM for PARP2, indicating high affinity (APExBIO). Inhibition prevents PARylation of target proteins, blocking recruitment of DNA repair machinery (Pettenger-Willey et al., 2026). This leads to accumulation of DNA damage, triggering cell cycle arrest and apoptosis, particularly in tumor cells with compromised DNA repair capacity. In preclinical models, ABT-888 potentiates the cytotoxic effects of DNA-damaging agents, including SN38 and oxaliplatin, by blocking repair of therapy-induced lesions (ABT-888: Potent PARP1/2 Inhibitor).

Evidence & Benchmarks

• ABT-888 inhibits PARP1 (Ki = 5.2 nM) and PARP2 (Ki = 2.9 nM) enzymatic activity in vitro (APExBIO product data).
• In colorectal cancer xenografts, ABT-888 combined with SN38 or oxaliplatin significantly delays tumor growth versus monotherapy (Pettenger-Willey et al., 2026).
• ABT-888 sensitizes MSI tumor models with MRE11 or RAD50 mutations to cytotoxic agents via synthetic lethality (Scenario-Driven Solutions for DNA Repair Inhibition).
• PARP inhibition by ABT-888 does not significantly modulate calicheamicin-induced cytotoxicity in acute leukemia cell lines, indicating pathway specificity (Pettenger-Willey et al., 2026).
• Compound purity validated at >99.5% by HPLC and NMR; molecular weight is 244.3, formula C₁₃H₁₆N₄O (APExBIO).

Applications, Limits & Misconceptions

ABT-888 is widely used in preclinical oncology to study DNA repair inhibition, chemosensitization, and synthetic lethality. Its selectivity enables mechanistic dissection of PARP-mediated DNA repair pathways. Applications include:

• Enhancing the efficacy of DNA-damaging chemotherapies in MSI tumor models and homologous recombination-deficient (HRD) cancers.
• Probing the DNA damage response (DDR) and caspase signaling pathways in cell-based assays.
• Developing translational strategies for combination therapies in resistant tumor types (Strategic PARP Inhibition with ABT-888 explains these strategies; this article provides updated benchmarks and specificity data).

However, several boundaries and misconceptions persist. See below:

Common Pitfalls or Misconceptions

• ABT-888 is not effective in tumor models where DNA repair pathways are intact; synthetic lethality depends on existing repair defects (Pettenger-Willey et al., 2026).
• PARP inhibition does not enhance cytotoxicity mediated by calicheamicin-based antibody–drug conjugates in acute leukemias (Pettenger-Willey et al., 2026).
• Not for diagnostic or therapeutic clinical use—research use only (APExBIO).
• Solubility in water is negligible; DMSO or ethanol with ultrasonic assistance is required for proper dissolution.
• Long-term storage of DMSO solutions is not recommended; prepare fresh stocks at -20°C for optimal stability.

Workflow Integration & Parameters

For experimental workflows, ABT-888 is typically dissolved in DMSO at concentrations >10 mM, using gentle warming and ultrasonic treatment to maximize solubility. Ethanol can also be used (≥10.6 mg/mL with ultrasonic assistance). The solid is best stored at -20°C in a desiccated environment. For cell-based assays, ABT-888 is added at nanomolar to low micromolar concentrations, often in combination with DNA-damaging agents. For in vivo models, dosing protocols should be referenced from peer-reviewed studies and adjusted for formulation and animal model (ABT-888: Potent PARP1/2 Inhibitor details dosing; this article provides updated solubility and storage guidance).

Researchers are advised to consult scenario-driven solutions and protocol Q&A for troubleshooting (Scenario-Driven Solutions for DNA Repair Inhibition offers practical guidance, while this article focuses on updated evidence and mechanistic specificity).

Conclusion & Outlook

ABT-888 (Veliparib) is a validated, high-purity PARP1/2 inhibitor supplied by APExBIO for research applications. It is most effective in models with DNA repair gene mutations and is a preferred tool for dissecting DDR and chemosensitization pathways. As research advances, careful benchmarking and protocol optimization remain essential for reproducible results. For full product details, visit the official ABT-888 (Veliparib) product page.